Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 57

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 57
---
of Ordinary Shares that we are authorized to issue, as the concept of authorized capital is no longer applicable under the provisions
of the Companies Act. There are no conversion rights, redemption provisions or sinking fund provisions relating to any Ordinary Shares.

We are not permitted under
English law to hold our own Ordinary Shares unless they are repurchased by us and held in treasury. We do not currently hold any of our
own Ordinary Shares.

History of Share Capital

Since January 1, 2022, our
issued share capital has changed as provided below.

On March 22, 2022, we issued
one Ordinary Share upon the exercise of one warrant issued in February 2019 to a certain institutional investor at an exercise price of
£200 per share.

On May 3, 2022, we issued
1,250 Ordinary Shares to be purchased under the Share Incentive Plan at £0.02 per share to the trust of our Share Incentive Plan.

On August 3, 2022, we issued
warrants to purchase 16,666 Ordinary Shares to a certain institutional investor at an exercise price of £2.70 per share.

On September 26, 2022, we
effected a ratio change to the Depositary Shares, pursuant to which the ratio of Ordinary Shares to Depositary Shares was changed such
that one Depositary Share represented 25 Ordinary Shares. Our Ordinary Shares were not affected by this change and no fractional Depositary
Shares were issued.

On December 16, 2022, we sold
to an institutional investor 492,400 Ordinary Shares represented by four Depositary Shares in a registered direct offering at $80,000.00
per Depositary Share, resulting in gross proceeds of approximately $0.4 million.

On February 15, 2023, we completed
the closing of a private placement, or the February Private Placement, pursuant to which we sold to certain institutional investors (1)
3,250,000 Ordinary Shares represented by 32 Depositary Shares at $46,400.00 per Depositary Share, (2) 12,931,020 Ordinary Shares
represented by 129 Depositary Shares, issuable upon the exercise of Series A warrants, or Series A Warrants, issued in the February Private
Placement at an exercise price of $53,600.00 per warrant, (3) 19,396,400 Ordinary Shares represented by 193 Depositary Shares, issuable
upon the exercise of Series B